Enterprise Value

-7.509M

Cash

92.75M

Avg Qtr Burn

-19.71M

Short % of Float

1.10%

Insider Ownership

19.59%

Institutional Own.

40.39%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
HB-400 Details
Hepatitis B

Phase 2

Initiation

HB-202/HB-201 Details
Cancer, Human papillomavirus

Phase 1/2

Data readout

HB-200 (TheraT® LCMV) + pembrolizumab Details
Cancer, Human papillomavirus, Head and neck squamous cell carcinoma

Phase 1/2

Data readout

HB-700 Details
Cancer, Lung cancer, Colorectal cancer , Pancreatic cancer

Phase 1

Initiation

HB-500 Details
Human immunodeficiency virus

Phase 1

Initiation

HB-101 (VaxWave®) Details
Cytomegalovirus, Infectious disease, Kidney transplantation

Failed

Discontinued

HB-300 Details
Cancer, Castration-resistant prostate cancer

Failed

Discontinued